|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001367,
umls-concept:C0021081,
umls-concept:C0022671,
umls-concept:C0024314,
umls-concept:C0035015,
umls-concept:C0149678,
umls-concept:C0205178,
umls-concept:C0209368,
umls-concept:C0442711,
umls-concept:C1292733,
umls-concept:C1524063,
umls-concept:C1548437,
umls-concept:C1882923
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1999-6-8
|
|
pubmed:abstractText |
A widely held view is that any increase in the potency of an immunosuppressive agent will lead to an increase in infection and malignancy, such as life-threatening Epstein-Barr virus (EBV) induced posttransplant lymphoproliferative disorders (PTLD). We tested this paradigm by studying the effect of adding mofetil to a steroid-free protocol under cover of high-dose aciclovir prophylaxis on the number of acute rejections, EBV infections and PTLDs after kidney transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1209-14
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10342310-Acute Disease,
pubmed-meshheading:10342310-Acyclovir,
pubmed-meshheading:10342310-Adolescent,
pubmed-meshheading:10342310-Adult,
pubmed-meshheading:10342310-Antilymphocyte Serum,
pubmed-meshheading:10342310-Antiviral Agents,
pubmed-meshheading:10342310-Child,
pubmed-meshheading:10342310-Female,
pubmed-meshheading:10342310-Graft Rejection,
pubmed-meshheading:10342310-Herpesviridae Infections,
pubmed-meshheading:10342310-Herpesvirus 4, Human,
pubmed-meshheading:10342310-Humans,
pubmed-meshheading:10342310-Immunosuppressive Agents,
pubmed-meshheading:10342310-Incidence,
pubmed-meshheading:10342310-Kidney Transplantation,
pubmed-meshheading:10342310-Lymphoproliferative Disorders,
pubmed-meshheading:10342310-Male,
pubmed-meshheading:10342310-Middle Aged,
pubmed-meshheading:10342310-Muromonab-CD3,
pubmed-meshheading:10342310-Mycophenolic Acid,
pubmed-meshheading:10342310-Prospective Studies,
pubmed-meshheading:10342310-Retrospective Studies
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
|
|
pubmed:affiliation |
Department of Nephrology, Odense University Hospital, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
